NEW YORK, Oct 3 – In the midst of an intellectual property battle with Affymetrix (Nasdaq: AFFX) over a non-PCR based RNA technology that researchers use in microarray-based gene expression analysis, Incyte Genomics (Nasdaq: INCY) said Tuesday it had licensed the related patents to American Home Products (NYSE: AHP) for internal use with Affy’s GeneChips.

AHP, a Madison, NJ-based pharmaceutical company, is also a subscriber to Incyte’s LifeSeq gene sequence database.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.